Lipigon Pharmaceuticals AB (publ) (FRA:9RP)
Germany flag Germany · Delayed Price · Currency is EUR
0.0038
+0.0002 (5.56%)
At close: Nov 28, 2025

FRA:9RP Statistics

Total Valuation

FRA:9RP has a market cap or net worth of EUR 5.27 million. The enterprise value is 3.75 million.

Market Cap5.27M
Enterprise Value 3.75M

Important Dates

The last earnings date was Friday, November 21, 2025.

Earnings Date Nov 21, 2025
Ex-Dividend Date n/a

Share Statistics

Current Share Class 605.93M
Shares Outstanding n/a
Shares Change (YoY) n/a
Shares Change (QoQ) n/a
Owned by Insiders (%) 1.13%
Owned by Institutions (%) 6.59%
Float 581.69M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 66.08
PB Ratio 3.86
P/TBV Ratio 3.86
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings -1.15
EV / Sales 46.78
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF -1.46

Financial Position

The company has a current ratio of 5.95

Current Ratio 5.95
Quick Ratio 5.80
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -139.12

Financial Efficiency

Return on equity (ROE) is -214.35% and return on invested capital (ROIC) is -139.39%.

Return on Equity (ROE) -214.35%
Return on Assets (ROA) -119.61%
Return on Invested Capital (ROIC) -139.39%
Return on Capital Employed (ROCE) -247.99%
Revenue Per Employee 11,384
Profits Per Employee -464,775
Employee Count7
Asset Turnover 0.05
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +3,700.00% in the last 52 weeks.

Beta (5Y) n/a
52-Week Price Change +3,700.00%
50-Day Moving Average 0.01
200-Day Moving Average 0.01
Relative Strength Index (RSI) 38.74
Average Volume (20 Days) n/a

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, FRA:9RP had revenue of EUR 79,687 and -3.25 million in losses.

Revenue79,687
Gross Profit -2.45M
Operating Income -3.39M
Pretax Income -3.25M
Net Income -3.25M
EBITDA -3.38M
EBIT -3.39M
Earnings Per Share (EPS) n/a
Full Income Statement

Balance Sheet

The company has 1.50 million in cash and n/a in debt, giving a net cash position of 1.50 million.

Cash & Cash Equivalents 1.50M
Total Debt n/a
Net Cash 1.50M
Net Cash Per Share n/a
Equity (Book Value) 1.36M
Book Value Per Share n/a
Working Capital 1.34M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -2.56 million and capital expenditures -9,769, giving a free cash flow of -2.57 million.

Operating Cash Flow -2.56M
Capital Expenditures -9,769
Free Cash Flow -2.57M
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin -4,247.91%
Pretax Margin -4,082.76%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

FRA:9RP does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield n/a
Shareholder Yield n/a
Earnings Yield -61.78%
FCF Yield -48.84%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score 1